PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
108.24%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-3.86%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-3.86%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-100.00%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
-1.12%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-1.49%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
3.86%
Operating income growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
No Data
No Data available this quarter, please select a different quarter.
-73.89%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-1.47%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-1.47%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
12.77%
EPS growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
13.49%
Diluted EPS growth 12-15% shows strong earnings power. Peter Lynch would examine growth drivers.
16.41%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
17.29%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.